HUMAN NEUROPEPTIDE-Y Y(1)-RECEPTOR ANTISENSE OLIGODEOXYNUCLEOTIDE SPECIFICALLY INHIBITS NEUROPEPTIDE Y-EVOKED VASOCONSTRICTION

被引:29
作者
ERLINGE, D
EDVINSSON, L
BRUNKWALL, J
YEE, F
WAHLESTEDT, C
机构
[1] LUND UNIV,DEPT INTERNAL MED,S-22101 LUND,SWEDEN
[2] LUND UNIV,DEPT EXPTL RES,S-22101 LUND,SWEDEN
[3] CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021
[4] LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-22101 LUND,SWEDEN
关键词
NEUROPEPTIDE-Y; BLOOD VESSEL (HUMAN); ANTISENSE; NEUROPEPTIDE-Y Y(1)-RECEPTOR;
D O I
10.1016/0014-2999(93)90548-V
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper describes a new approach for the development of an inhibitor of the contractile responses of neuropeptide Y in human blood vessels by the use of an antisense oligodeoxynucleotide complementary to human neuropeptide Y Y1 receptor mRNA. One micromolar of an antisense 18-base oligodeoxynucleotide (hY1-AS), corresponding to the human Y1 receptor NH2-terminus, was incubated with segments of human subcutaneous arteries and veins for 48 h at 37-degrees-C. Control vessels were incubated with the corresponding sense oligodeoxynucleotide (hY1-S) or a 3-base mismatched antisense oligodeoxynucleotide (hY1-MM) or no oligodeoxynucleotide. The contractile response to neuropeptide Y was markedly attenuated in both arteries and veins after treatment with hY1-AS, but was unaffected by hY1-S or hY1-MM. The pD2 values, i.e. the potency of neuropeptide Y, did not differ in hY1-AS treated vessels, suggesting a non-competitive receptor interaction as a result of down-regulation of Y1 receptors. Responses to noradrenaline or high K+ were unaffected by hY1-AS. This study may represent a new and highly specific approach to vascular pharmacology.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 10 条
  • [1] EFFECTS OF NEUROPEPTIDE-Y ON THE CARDIOVASCULAR-SYSTEM
    EDVINSSON, L
    HAKANSON, R
    WAHLESTEDT, C
    UDDMAN, R
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (06) : 231 - 235
  • [2] INNERVATION OF HUMAN OMENTAL ARTERIES AND VEINS AND VASOMOTOR RESPONSES TO NORADRENALINE, NEUROPEPTIDE-Y, SUBSTANCE-P AND VASOACTIVE INTESTINAL PEPTIDE
    EDVINSSON, L
    HAKANSON, R
    STEEN, S
    SUNDLER, F
    UDDMAN, R
    WAHLESTEDT, C
    [J]. REGULATORY PEPTIDES, 1985, 12 (01) : 67 - 79
  • [3] NEUROPEPTIDE Y-LIKE IMMUNOREACTIVITY AND HYPERTENSION
    ERLINGE, D
    EKMAN, R
    THULIN, T
    EDVINSSON, L
    [J]. JOURNAL OF HYPERTENSION, 1992, 10 (10) : 1221 - 1225
  • [4] CHARACTERIZATION OF VASCULAR NEUROPEPTIDE-Y RECEPTORS
    GRUNDEMAR, L
    JONAS, SE
    MORNER, N
    HOGESTATT, ED
    WAHLESTEDT, C
    HAKANSON, R
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1992, 105 (01) : 45 - 50
  • [5] LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935
  • [6] VASOCONSTRICTOR EFFECTS INVIVO AND PLASMA DISAPPEARANCE RATE OF NEUROPEPTIDE-Y IN MAN
    PERNOW, J
    LUNDBERG, JM
    KAIJSER, L
    [J]. LIFE SCIENCES, 1987, 40 (01) : 47 - 54
  • [7] LOCALIZATION OF Y1-RECEPTORS FOR NPY AND PYY ON VASCULAR SMOOTH-MUSCLE CELLS IN RAT PANCREAS
    SHEIKH, SP
    ROACH, E
    FUHLENDORFF, J
    WILLIAMS, JA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (02): : G250 - G257
  • [8] ELEVATED INSULIN, NOREPINEPHRINE, AND NEUROPEPTIDE-Y IN HYPERTENSION
    SOLT, VB
    BROWN, MR
    KENNEDY, B
    KOLTERMAN, OG
    ZIEGLER, MG
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1990, 3 (11) : 823 - 828
  • [9] MODULATION OF ANXIETY AND NEUROPEPTIDE-Y-Y1 RECEPTORS BY ANTISENSE OLIGODEOXYNUCLEOTIDES
    WAHLESTEDT, C
    PICH, EM
    KOOB, GF
    YEE, F
    HEILIG, M
    [J]. SCIENCE, 1993, 259 (5094) : 528 - 531
  • [10] WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309